These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15957734)

  • 1. Activated protein C for the treatment of fulminant meningococcal septicaemia.
    Thomas GL; Wigmore T; Clark P
    Anaesth Intensive Care; 2004 Apr; 32(2):284-7. PubMed ID: 15957734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early treatment with activated protein C for meningococcal septic shock: case report and literature review.
    Hasin T; Leibowitz D; Rot D; Weiss Y; Chajek-Shaul T; Nir-Paz R
    Intensive Care Med; 2005 Jul; 31(7):1002-3. PubMed ID: 15905995
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et al.
    Thomas GL; Clark P
    Intensive Care Med; 2005 Dec; 31(12):1729; author reply 1730. PubMed ID: 16283165
    [No Abstract]   [Full Text] [Related]  

  • 4. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.
    de Kleijn ED; de Groot R; Hack CE; Mulder PG; Engl W; Moritz B; Joosten KF; Hazelzet JA
    Crit Care Med; 2003 Jun; 31(6):1839-47. PubMed ID: 12794428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation.
    Lignell A; Siegbahn A; Stridsberg M; Pauksen K; Gedeborg R; Sjölin J
    Acta Anaesthesiol Scand; 2003 Aug; 47(7):897-900. PubMed ID: 12859313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.
    White B; Livingstone W; Murphy C; Hodgson A; Rafferty M; Smith OP
    Blood; 2000 Dec; 96(12):3719-24. PubMed ID: 11090052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein C administration in meningococcal septicaemia.
    Bhandari S
    Nephrol Dial Transplant; 1998 Sep; 13(9):2421-2. PubMed ID: 9761547
    [No Abstract]   [Full Text] [Related]  

  • 8. Meningococcal septicaemia: treatment with protein C concentrate.
    Clarke RC; Johnston JR; Mayne EE
    Intensive Care Med; 2000 Apr; 26(4):471-3. PubMed ID: 10872142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal perforation complicating meningococcal disease.
    Britto J; Nadel S; Habibi P; Levin M
    Pediatr Infect Dis J; 1995 May; 14(5):393-4. PubMed ID: 7638017
    [No Abstract]   [Full Text] [Related]  

  • 10. Continuing challenges of sepsis research.
    Crowther MA; Marshall JC
    JAMA; 2001 Oct; 286(15):1894-6. PubMed ID: 11597294
    [No Abstract]   [Full Text] [Related]  

  • 11. Protein C in the treatment of coagulopathy in meningococcal sepsis.
    Betrosian AP; Balla M; Kofinas G; Papanikolaou M; Georgiadis G
    Crit Care Med; 1999 Dec; 27(12):2849-50. PubMed ID: 10628651
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator.
    Zenz W; Muntean W; Zobel G; Grubbauer HM; Gallistl S
    Thromb Haemost; 1995 Aug; 74(2):802-3. PubMed ID: 8585030
    [No Abstract]   [Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans.
    Bachli EB; Vavricka SR; Walter RB; Leschinger MI; Maggiorini M
    Intensive Care Med; 2003 Feb; 29(2):337. PubMed ID: 12594601
    [No Abstract]   [Full Text] [Related]  

  • 14. Should steroids be used in children with meningococcal shock?
    Branco RG; Russell RR
    Arch Dis Child; 2005 Nov; 90(11):1195-6. PubMed ID: 16243881
    [No Abstract]   [Full Text] [Related]  

  • 15. [Replacement therapy with protein C for meningococcal sepsis and fulminant purpura in pediatric patients].
    Llinares Tello F; Hernández Prats C; Burgos San José A; Bosacoma Ros N; Alcalá Minagorre P; López Rodríguez F; Reig Sáenz R; Marco Vera P; Ordovás Baines JP
    Farm Hosp; 2004; 28(2):130-6. PubMed ID: 15101805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Toxic shock syndrome consecutive to the presence of vaginal tampon for menstruation regressive after early haemodynamic optimization and activated protein C infusion].
    Ellies E; Vallée F; Mari A; Silva S; Bauriaud R; Fourcade O; Genestal M
    Ann Fr Anesth Reanim; 2009 Jan; 28(1):91-5. PubMed ID: 19108981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits.
    Roback MG; Stack AM; Thompson C; Brugnara C; Schwarz HP; Saladino RA
    Shock; 1998 Feb; 9(2):138-42. PubMed ID: 9488260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal disease: clinical presentation and sequelae.
    Pace D; Pollard AJ
    Vaccine; 2012 May; 30 Suppl 2():B3-9. PubMed ID: 22607896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated protein C in patients with septic shock: a consecutive case series.
    Wagner JA; Langenfeld H; Klett L; Störk S
    Int J Clin Pharm; 2012 Feb; 34(1):23-6. PubMed ID: 22120699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock.
    Leclerc F; Cremer R; Leteurtre S; Martinot A; Fourier C
    Crit Care Med; 2000 May; 28(5):1694-7. PubMed ID: 10834762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.